

## NOTICE OF DATE OF ANNUAL GENERAL MEETING AND OTHER RELEVANT DATES

**Melbourne, Australia – 28 August 2025:** Pursuant to ASX Listing Rule 3.13.1 Percheron Therapeutics Limited (ASX: PER) (**Percheron** or the **Company**) is pleased to advise the following details in relation to the Company's forthcoming Annual General Meeting (**AGM**).

<b>Date and time for the AGM</b>	Wednesday 22 October 2025 10:00am (AEDT)
<b>Date of Notice of Meeting dispatch</b>	Monday 22 September 2025
<b>Last date for receipt of nomination as a Director</b>	Tuesday 2 September 2025

Further details in relation to the AGM, including items of business to be voted upon by shareholders, and instructions on how shareholders may attend and vote at the meeting (including on how to appoint a proxy), will be provided in the Notice of Meeting (**NOM**). In accordance with section 253RA(2) of the *Corporations Act 2001* (Cth), the Company will not be sending hard copies of the NOM to shareholders unless a shareholder has requested a hard copy. A copy of the NOM will be available on the Company's website at [www.PercheronTx.com](http://www.PercheronTx.com).

The Company's Appendix 4E, together with the FY 2025 Annual Report were released to the ASX on 28 August 2025 and can be accessed and downloaded from the Company's website here [www.percherontx.com](http://www.percherontx.com). Shareholders may obtain a hard copy of the Annual Report by emailing a request to the Company Secretary at [deborah.ambrosini@percherontx.com](mailto:deborah.ambrosini@percherontx.com).

The Company looks forward to shareholder participation at this year's AGM.

~ ENDS ~

---

### About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well tolerated, and Percheron aims to commence further clinical trials in CY2026. For further information, please see our website at [www.PercheronTx.com](http://www.PercheronTx.com), or email [info@PercheronTx.com](mailto:info@PercheronTx.com).

***This announcement has been authorised for release to the Australian Securities Exchange by Ms Deborah Ambrosini, Company Secretary, Percheron Therapeutics.***

---